Long-term survival of adults with B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) after treatment with blinatumomab and subsequent allogeneic hematopoietic stem cell transplantation (HSCT)

Authors :: Anthony S. Stein
Hervé Dombret
Nicola Gökbuget
Ralf C. Bargou
Massimiliano Bonifacio
Xiaoyu Dong
Monika Brueggemann
Hagop M. Kantarjian
Gerhard Zugmaier
Max S. Topp
Source :: Journal of Clinical Oncology. 36:7044-7044
Publication Year :: 2018
Publisher :: American Society of Clinical Oncology (ASCO), 2018.
Abstract: 7044Background: In BCP-ALL, blinatumomab has demonstrated efficacy in two phase 2 trials: MT 103 -203 (Gokbuget et al, Blood 2017) in minimal residual disease (MRD) and MT 102 – 211 in relapsed/ref...

Tools